{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:56:03Z","timestamp":1787313363703,"version":"build-2736575974"},"reference-count":37,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,2,1]]},"abstract":"<jats:p>Objective. Our aim was to compare the 12-month safety and efficacy of fluticasone propionate (FP) and sodium cromoglycate (SCG) in children aged 1 to 3 years with mild to moderate recurrent wheeze.<\/jats:p>\n                  <jats:p>Methods. The study was a randomized, parallel-group, open-label multicenter study of 625 children, aged 1 to 3 years, with recurrent wheeze randomized in a 3:1 ratio to treatment for 52 weeks with FP (100 \u03bcg twice daily) via metered-dose inhaler and Babyhaler spacer device or SCG (5 mg 4 times daily) via metered-dose inhaler and Nebuhaler spacer device, respectively.<\/jats:p>\n                  <jats:p>Results. There was no significant difference in mean adjusted growth rates between the 2 groups: 84.0 mm\/year in the FP group versus 86.4 mm\/year in the SCG group (difference FP-SCG: \u22122.4 mm\/year; 95% confidence interval: \u22126.6 to 1.8). Growth comparisons were independent of age, gender, previous use of steroid, or whether measured as length and\/or height. Serum and urinary cortisol concentrations showed a statistically significant suppression of 10% and 14%, respectively, but the number of patients with serum cortisol levels below the lower normal limit was reduced during the trial. Both treatments were well tolerated. The most common drug-related adverse events were cough (2% FP vs 1% SCG) and hoarseness (1% FP vs 0% SCG). One incident of cataract was observed at baseline and 1 after FP treatment; the latter had resolved after 12 months. The efficacy of FP was superior to SCG with fewer cases of symptom worsening, exacerbations, and requirements for oral steroid treatment and more symptom-free days and days without use of rescue treatment.<\/jats:p>\n                  <jats:p>Conclusions. Twelve months of treatment with inhaled FP (100 \u03bcg twice daily) in preschool children aged 1 to 3 years with recurrent wheeze has no effect on growth and no other clinically important side effects but is more efficacious than SCG.<\/jats:p>","DOI":"10.1542\/peds.113.2.e87","type":"journal-article","created":{"date-parts":[[2004,8,13]],"date-time":"2004-08-13T20:53:04Z","timestamp":1092430384000},"page":"e87-e94","source":"Crossref","is-referenced-by-count":119,"title":["Twelve-Month Safety and Efficacy of Inhaled Fluticasone Propionate in Children Aged 1 to 3 Years With Recurrent Wheezing"],"prefix":"10.1542","volume":"113","author":[{"given":"Hans","family":"Bisgaard","sequence":"first","affiliation":[{"name":"Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Allen","sequence":"additional","affiliation":[{"name":"University of Wisconsin Children\u2019s Hospital, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"Milanowski","sequence":"additional","affiliation":[{"name":"Klinika Choro\u0301b Puc, Lublin, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilia","family":"Kalev","sequence":"additional","affiliation":[{"name":"Medical University Pediatric Hospital of Pulmonary Disease, Sofia, Bulgaria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Willits","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Greenford, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Davies","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Greenford, Middlesex, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2004,2,1]]},"reference":[{"key":"2021121011032013100_R1","unstructured":"Global Strategy for Asthma Management and Prevention. NHLBI\/WHO Workshop Report. NIH Publication No. 95-3659, Bethesda, MD: National Institutes of Health; 2002"},{"key":"2021121011032013100_R2","doi-asserted-by":"crossref","unstructured":"Noble V, Ruggins N, Everard M, Milner A. Inhaled budesonide for chronic wheezing under 18 months of age. Arch Dis Child.1992;67:285\u2013288","DOI":"10.1136\/adc.67.3.285"},{"key":"2021121011032013100_R3","doi-asserted-by":"crossref","unstructured":"Connett G, Warde C, Wooler E, Lenney W. Use of budesonide in severe asthmatics aged 1\u20133 years. Arch Dis Child.1993;69:351\u2013355","DOI":"10.1136\/adc.69.3.351"},{"key":"2021121011032013100_R4","doi-asserted-by":"crossref","unstructured":"Bisgaard H, Gillies J, Groenewald M, Maden C. The effect of inhaled fluticasone propionate in the treatment of young asthmatic children: a dose comparison study. Am J Respir Crit Care Med.1999;160:126\u2013131","DOI":"10.1164\/ajrccm.160.1.9811024"},{"key":"2021121011032013100_R5","doi-asserted-by":"crossref","unstructured":"Bisgaard H, Munck S, Nielsen J, Petersen W, Ohlsson S. Inhaled budesonide for treatment of recurrent wheezing in early childhood. Lancet.1990;336:649\u2013651","DOI":"10.1016\/0140-6736(90)92147-A"},{"key":"2021121011032013100_R6","doi-asserted-by":"crossref","unstructured":"Buchvald F, Bisgaard H. FeNO measured at fixed exhalation flow rate during controlled tidal breathing in children from the age of 2 yr. Am J Respir Crit Care Med.2001;163:699\u2013704","DOI":"10.1164\/ajrccm.163.3.2004233"},{"key":"2021121011032013100_R7","doi-asserted-by":"crossref","unstructured":"Nielsen K, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year old asthmatic children. Am J Respir Crit Care Med.2000;162:1500\u20131506","DOI":"10.1164\/ajrccm.162.4.2002019"},{"key":"2021121011032013100_R8","doi-asserted-by":"crossref","unstructured":"Bisgaard H, Price M, Maden C, Olsen N. Cost-effectiveness of fluticasone propionate administered via metered-dose inhaler plus Babyhaler spacer in the treatment of asthma in pre-school aged children. Chest.2001;120:1835\u20131842","DOI":"10.1378\/chest.120.6.1835"},{"key":"2021121011032013100_R9","doi-asserted-by":"crossref","unstructured":"Agertoft L, Pedersen S. Short-term knemometry and urine cortisol excretion in children treated with fluticasone propionate and budesonide: a dose response study. Eur Respir J.1997;10:1507\u20131512","DOI":"10.1183\/09031936.97.10071507"},{"key":"2021121011032013100_R10","doi-asserted-by":"crossref","unstructured":"Doull I, Freezer N, Holgate S. Growth of prepubertal children with mild asthma treated with inhaled beclomethasone dipropionate. Am J Respir Crit Care Med.1995;151:1715\u20131719","DOI":"10.1164\/ajrccm.151.6.7767512"},{"key":"2021121011032013100_R11","doi-asserted-by":"crossref","unstructured":"Verberne A, Frost C, Roorda R, vanderLaag H, Kerrebijm K. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med.1997;156:688\u2013695","DOI":"10.1164\/ajrccm.156.3.9611067"},{"key":"2021121011032013100_R12","doi-asserted-by":"crossref","unstructured":"Simons F. A comparison of beclomethasone, salmeterol, and placebo in children with asthma. Canadian Beclomethasone Dipropionate-Salmeterol Xinafoate Study Group. N Engl J Med.1997;4:1659\u20131665","DOI":"10.1056\/NEJM199712043372304"},{"key":"2021121011032013100_R13","doi-asserted-by":"crossref","unstructured":"Tinkelman D, Reed C, Nelson H, Offord K. Aerosol beclomethasone dipropionate compared to theophylline as primary treatment of chronic, mild to moderately severe asthma in children. Pediatrics.1993;92:64\u201377","DOI":"10.1542\/peds.92.1.64"},{"key":"2021121011032013100_R14","doi-asserted-by":"crossref","unstructured":"Allen D, Bronsky E, LaForce C, et al. Growth in asthmatic children treated with fluticasone propionate. Fluticasone propionate Asthma Study Group. J Pediatr.1998;132:472\u2013477","DOI":"10.1016\/S0022-3476(98)70023-X"},{"key":"2021121011032013100_R15","doi-asserted-by":"crossref","unstructured":"Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med.2000;343:1054\u20131063","DOI":"10.1056\/NEJM200010123431501"},{"key":"2021121011032013100_R16","doi-asserted-by":"crossref","unstructured":"Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med.2000;343:1064\u20131069","DOI":"10.1056\/NEJM200010123431502"},{"key":"2021121011032013100_R17","doi-asserted-by":"crossref","unstructured":"Skoner D, Szefler S, Welch M, Walton-Bowen K, Cruz-Rivera M, Smith J. Longitudinal growth in infants and young children treated with budesonide inhalation suspension for persistent asthma. J Allergy Clin Immunol.2000;105:259\u2013268","DOI":"10.1016\/S0091-6749(00)90074-5"},{"key":"2021121011032013100_R18","doi-asserted-by":"crossref","unstructured":"Turktas I, Ozkaya O, Bostanci I, Bideci A, Cinaz P. Safety of inhaled corticosteroid therapy in young children with asthma. Ann Allergy Asthma Immunol.2001;86:649\u2013654","DOI":"10.1016\/S1081-1206(10)62293-4"},{"key":"2021121011032013100_R19","doi-asserted-by":"crossref","unstructured":"Volovitz B, Amir J, Malik H, Kauschanski A, Varsano I. Growth and pituitary-adrenal function in children with severe asthma treated with inhaled budesonide. N Engl J Med.1993;329:1731\u20131733","DOI":"10.1056\/NEJM199312023292305"},{"key":"2021121011032013100_R20","doi-asserted-by":"crossref","unstructured":"Bisgaard H. Systemic activity from inhaled topical steroid in toddlers studied by knemometry. Acta Paediatr Scand.1993;82:1066\u20131071","DOI":"10.1111\/j.1651-2227.1993.tb12814.x"},{"key":"2021121011032013100_R21","doi-asserted-by":"crossref","unstructured":"Anh\u00f8j J, Bisgaard A, Bisgaard H. Systemic activity of inhaled steroids in asthmatic young children 1\u20133 years of age. Pediatrics.2002;109(3). Available at: pediatrics.aappublications.org\/cgi\/content\/full\/109\/3\/e40","DOI":"10.1542\/peds.109.3.e40"},{"key":"2021121011032013100_R22","unstructured":"Guideline for Industry: The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life threatening conditions. ICH-EIA. 95\u20134958, 11269\u201311271; 1995"},{"key":"2021121011032013100_R23","unstructured":"Boys and Girls Growth Charts. London, UK: Child Growth Foundation; 1990"},{"key":"2021121011032013100_R24","doi-asserted-by":"crossref","unstructured":"Callejas S, Biddlecombe R, Jones A, Joyce K, Pereira A, Pleasance S. Determination of the glucocorticoid fluticasone propionate in plasma by automated solid-phase extraction and liquid chromatography tandem mass spectrometry. J Chromatogr Biomed Sci Appl.1998;718:243\u2013250","DOI":"10.1016\/S0378-4347(98)00374-0"},{"key":"2021121011032013100_R25","unstructured":"Goldstein H. Multilevel statistical models, Kendall\u2019s Library of Statistics 3. 1995"},{"key":"2021121011032013100_R26","doi-asserted-by":"crossref","unstructured":"Martinez F. Present and future treatment of asthma in infants and young children. J Allergy Clin Immunol.1999;104:169\u2013174","DOI":"10.1016\/S0091-6749(99)70058-8"},{"key":"2021121011032013100_R27","doi-asserted-by":"crossref","unstructured":"Hindmarsh P. Exogenous glucocorticoids influence adrenal function, but assessment can be difficult. BMJ.2002;324:1083","DOI":"10.1136\/bmj.324.7345.1081"},{"key":"2021121011032013100_R28","doi-asserted-by":"crossref","unstructured":"Crowley S, Hindmarsh PC, Honour JW, Brook CG. Reproducibility of the cortisol response to stimulation with a low dose of ACTH(1\u201324): the effect of basal cortisol levels and comparison of low-dose with high-dose secretory dynamics. J Endocrinol.1993;136:167\u2013172","DOI":"10.1677\/joe.0.1360167"},{"key":"2021121011032013100_R29","doi-asserted-by":"crossref","unstructured":"Drake AJ, Howells RJ, Shield JPH, Prendiville A, Ward PS, Crowne EC. Symptomatic adrenal insufficiency presenting with hypoglycaemia in children with asthma receiving high dose inhaled fluticasone propionate. BMJ.2002;324:1081\u20131083","DOI":"10.1136\/bmj.324.7345.1081"},{"key":"2021121011032013100_R30","doi-asserted-by":"crossref","unstructured":"Todd GRG, Acerini CL, Buck JJ, et al. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J.2002;19:1207\u20131209","DOI":"10.1183\/09031936.02.00274402"},{"key":"2021121011032013100_R31","doi-asserted-by":"crossref","unstructured":"Patel L, Wales JK, Kibirige MS, et al. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child.2001;85:330\u2013334","DOI":"10.1136\/adc.85.4.330"},{"key":"2021121011032013100_R32","doi-asserted-by":"crossref","unstructured":"Stewart-Brown S, Haslum M. Partial sight and blindness in children of the 1970 birth cohort at 10 years of age. J Epidemiol Community Health.1988;42:17\u201323","DOI":"10.1136\/jech.42.1.17"},{"key":"2021121011032013100_R33","doi-asserted-by":"crossref","unstructured":"Stayte M, Reeves B, Wortham C. Ocular and vision defects in pre-school children. Br J Ophthalmol.1993;77:228\u2013232","DOI":"10.1136\/bjo.77.4.228"},{"key":"2021121011032013100_R34","doi-asserted-by":"crossref","unstructured":"Knorr B, Franchi L, Bisgaard H, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics.2001;108:1\u201310","DOI":"10.1542\/peds.108.3.e48"},{"key":"2021121011032013100_R35","doi-asserted-by":"crossref","unstructured":"de Blic J, Delacourt C, Le Bourgeois M, et al. Efficacy of nebulized budesonide in the treatment of severe infantile asthma: a double blind study. J Allergy Clin Immunol.1996;98:14\u201320","DOI":"10.1016\/S0091-6749(96)70221-X"},{"key":"2021121011032013100_R36","doi-asserted-by":"crossref","unstructured":"Roorda R, Mezei G, Bisgaard H, Maden C. Response of preschool children with asthma symptoms to fluticasone propionate. J Allergy Clin Immunol.2001;108:540\u2013546","DOI":"10.1067\/mai.2001.118789"},{"key":"2021121011032013100_R37","doi-asserted-by":"crossref","unstructured":"Mellon M. Efficacy of budesonide inhalation suspension in infants and young children with persistent asthma. Budesonide Inhalation Suspension Study Group. J Allergy Clin Immunol.1999;104:191\u2013199","DOI":"10.1016\/S0091-6749(99)70061-8"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/2\/e87\/1011253\/zpe00204000e87.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/113\/2\/e87\/1011253\/zpe00204000e87.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T01:44:43Z","timestamp":1682732683000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/113\/2\/e87\/66912\/Twelve-Month-Safety-and-Efficacy-of-Inhaled"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2,1]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2004,2,1]]},"published-print":{"date-parts":[[2004,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.113.2.e87","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2,1]]}}}